Posaconazole for treatment of refractory invasive fungal disease

Mycoses. 2006:49 Suppl 1:37-41. doi: 10.1111/j.1439-0507.2006.01301.x.

Abstract

Invasive fungal infections are usually associated with immunocompromised states About 40-60% of these patients are refractory to standard antifungal therapy We describe the effect of posaconazole in the treatment of a 12 years-old girl with uncontrolled diabetes mellitus with life-threatening cerebral mucor mycosis and a 4 year old girl boy with chronic granulomatous disease presenting with invasive Aspergillus nidulans infection.

Publication types

  • Case Reports

MeSH terms

  • Antifungal Agents / administration & dosage
  • Antifungal Agents / therapeutic use*
  • Aspergillosis / drug therapy*
  • Aspergillosis / microbiology
  • Aspergillus nidulans / drug effects
  • Aspergillus nidulans / isolation & purification
  • Central Nervous System Fungal Infections / drug therapy*
  • Central Nervous System Fungal Infections / microbiology
  • Child
  • Child, Preschool
  • Diabetes Mellitus, Type 1 / complications
  • Drug Resistance, Fungal
  • Female
  • Granulomatous Disease, Chronic / complications
  • Humans
  • Immunocompromised Host
  • Lung Diseases, Fungal / drug therapy*
  • Lung Diseases, Fungal / microbiology
  • Male
  • Mucormycosis / drug therapy*
  • Mucormycosis / microbiology
  • Rhizopus / drug effects
  • Rhizopus / isolation & purification
  • Sinusitis / drug therapy*
  • Sinusitis / microbiology
  • Treatment Outcome
  • Triazoles / administration & dosage
  • Triazoles / therapeutic use*

Substances

  • Antifungal Agents
  • Triazoles
  • posaconazole